Subsidised Access to Research and Manufacturing Facilities
for Eligible Researchers
Through the National Collaborative Research Infrastructure Strategy (NCRIS), the Commonwealth Government and State Government partners have enhanced Australia's capacity to produce recombinant proteins in pre-commercial quantities. NCRIS Capability 5.5 Biotechnology Products offers eligible researchers access to quality facilities, advanced equipment and technical expertise at a subsidised rate.
The goal of this project is to bridge the gap between biotherapeutics drug discovery and clinical research by providing Australian researchers working in the field of recombinant proteins with access to the appropriate support structures required to progress their research along the development pipeline.
Protein expression, purification and characterisation capabilities in Australia have been enhanced by the establishment of 'feeder' process development nodes in Queensland, New South Wales and Victoria.
Process Development Facilities (Feeder Facilities):
Facility upgrades of two GMP manufacturing facilities has increased capacity available for eligible researchers requiring production and 'fill and finish' of clinical grade material.
GMP Manufacturing Facilities:
To learn more about the facilities and services please visit our Facilities page.
AusBiotech Ltd
AusBiotech is the managing agency for this project and is responsible for the allocation of Commonwealth funding that has facilitated the development and utilisation of the facilities across Australia. When State government and host institution contributions are considered the overall recombinant proteins project value is $41 million.
This project is supported by the following Governments
